Innovations in Pelvic Organ Prolapse Management: From Diagnosis to Recovery

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 461

Special Issue Editors


E-Mail Website
Guest Editor
Urogynecology Unit, 1st Department of Obstetrics & Gynecology, “Alexandra” General Hospital, National and Kapodistrian University of Athens, Lourou 2, 11528 Athens, Greece
Interests: urogynecology; pelvic floor repair; female sexual dysfunction; overactive bladder; gynecologic surgery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Urogynecology Unit, 1st Department of Obstetrics & Gynecology, “Alexandra” General Hospital, National and Kapodistrian University of Athens, Lourou 2, 11528 Athens, Greece
Interests: pelvic organ prolapse; urinary incontinence; gynecologic surgery; minimally invasive gynecology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor Assistant
Minimally Invasive Gynecologic Surgery Unit, 1st Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, “Alexandra” General Hospital, Vasilissis Sofias Avenue 80, 11528 Athens, Greece
Interests: gynecological surgery; urogynecology; laparoscopic surgery; pelvic reconstructive surgery; female urology; reproductive medicine; endometriosis; minimally invasive surgery; robotic surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pelvic organ prolapse (POP) affects a significant proportion of women, especially in the postmenopausal period, with a growing prevalence due to aging populations. This condition is multifactorial, involving both anatomical and functional aspects of the pelvic floor. Its management remains a major focus in urogynecology, requiring individualized treatment plans and a deep understanding of pelvic floor dysfunction.

This Special Issue aims to explore contemporary advances in diagnosis, surgical repair, and functional rehabilitation of pelvic organ prolapse. Emphasis will be given to evidence-based approaches that improve long-term anatomical outcomes and enhance quality of life, while also reducing morbidity and recurrence.

We welcome contributions on native tissue repairs, mesh-free and mesh-based techniques, evaluation of sexual and urinary function outcomes, role of imaging and urodynamics in surgical planning, and novel approaches in the assessment of patient-reported outcomes in prolapse surgery.           

This Special Issue welcomes a wide range of high-quality submissions related to pelvic organ prolapse, particularly in the field of urogynecology. We are interested in the following:

  • Original research articles presenting clinical studies, surgical outcomes, or functional evaluations relevant to POP management.
  • Systematic reviews and meta-analyses that synthesize current evidence and provide guidance for clinical practice.
  • Narrative reviews or expert opinion papers offering critical perspectives on evolving concepts, controversies, or future directions in the field.
  • Surgical technique descriptions or video articles demonstrating procedural approaches or innovations in POP repair.
  • Multidisciplinary or translational studies bridging urogynecology with imaging, physiotherapy, urodynamics, or quality-of-life research.

We look forward to your submissions.

Dr. Themos Grigoriadis
Dr. Dimitrios Zacharakis
Guest Editors

Dr. Athanasios Douligeris
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urogynecology
  • pelvic organ prolapse
  • reconstructive pelvic surgery
  • vaginal surgery
  • urinary incontinence
  • pelvic floor dysfunction
  • urodynamcs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 529 KiB  
Article
Is the Addition of CO2 Laser to β3-Adrenoceptor Agonist Mirabegron Effective in the Management of Overactive Bladder? Results of a Randomized Controlled Trial
by Konstantinos Kypriotis, Anastasia Prodromidou, Stavros Athanasiou, Dimitrios Zacharakis, Nikolaos Kathopoulis, Athanasios Douligeris, Veatriki Athanasiou, Lina Michala and Themos Grigoriadis
Medicina 2025, 61(7), 1198; https://doi.org/10.3390/medicina61071198 - 30 Jun 2025
Viewed by 322
Abstract
Background and Objectives: This study aimed to assess whether the addition of fractional CO2 laser therapy to standard pharmacologic treatment with Mirabegron, a β3-adrenoceptor agonist, enhances the clinical outcomes in the management of overactive bladder syndrome (OAB) in postmenopausal women. Materials [...] Read more.
Background and Objectives: This study aimed to assess whether the addition of fractional CO2 laser therapy to standard pharmacologic treatment with Mirabegron, a β3-adrenoceptor agonist, enhances the clinical outcomes in the management of overactive bladder syndrome (OAB) in postmenopausal women. Materials and Methods: Τhis was a prospective, randomized, double-blind, sham-controlled trial including 50 postmenopausal women with moderate-to-severe OAB symptoms. Participants were randomized (1:1) to receive mirabegron 50 mg daily in combination with either active fractional CO2 laser therapy (Group A) or sham laser treatment (Group B). Both groups underwent three monthly sessions of vaginal laser treatment and were followed for a total of four months. Clinical assessments were performed at baseline and monthly visits (T0–T3), using validated instruments including the Overactive Bladder Questionnaire (OAB-q), King’s Health Questionnaire (KHQ), Urinary Distress Inventory (UDI-6), Pelvic Floor Impact Questionnaire (PFIQ-7), Patient Global Impression of Improvement (PGI-I), and 3-day voiding diaries. The trial was registered at ClinicalTrials.gov (Identifier: NCT03846895). Results: Significant symptom improvement was observed within both groups over time, with reductions in urinary frequency, urgency, nocturia, and incontinence episodes, as well as improvements in quality-of-life scores. However, intergroup comparisons revealed no statistically significant differences in any primary or secondary outcomes. Both treatment modalities demonstrated similar effectiveness across all measured parameters. Conclusions: In this randomized controlled trial, the adjunctive use of fractional CO2 laser therapy did not offer additional clinical benefit beyond mirabegron monotherapy in the short-term management of OAB. These findings underscore the need for further investigation into tailored therapeutic strategies, particularly in populations with overlapping genitourinary syndrome of menopause or more refractory OAB symptoms. Full article
Show Figures

Figure 1

Back to TopTop